Protalix BioTherapeutics, Inc. (PLX) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 33.75M | 9.12M | 17.85M | 15.66M | 10.11M | 18.22M | 17.96M | 13.47M | 3.75M | 10.49M | 10.35M | 35.08M |
| Revenue Growth % | 233.73% | -49.93% | -0.6% | 16.21% | 169.82% | 73.74% | 73.6% | -61.59% | -60.91% | 21.69% | -27.06% | 300.72% |
| Cost of Goods Sold | 4.13M | 4.62M | 8.32M | 5.87M | 8.18M | 3.89M | 8.38M | 9.46M | 2.6M | 8.86M | 4.89M | 6.15M |
| COGS % of Revenue | 12.23% | 50.64% | 46.63% | 37.49% | 80.89% | 21.33% | 46.63% | 70.18% | 69.42% | 84.46% | 47.3% | 17.53% |
| Gross Profit | 29.62M | 4.5M | 9.53M | 9.79M | 1.93M | 14.33M | 9.58M | 4.02M | 1.15M | 1.63M | 5.45M | 28.93M |
| Gross Margin % | 87.77% | 49.36% | 53.37% | 62.51% | 19.11% | 78.67% | 53.37% | 29.82% | 30.58% | 15.54% | 52.7% | 82.47% |
| Gross Profit Growth % | 1432.49% | -68.58% | -0.59% | 143.6% | 68.67% | 779.26% | 75.79% | -86.11% | -82.38% | -73.79% | -23.31% | 519.95% |
| Operating Expenses | 8.48M | 9.16M | 7.4M | 8.62M | 6.08M | 7.12M | 5.59M | 6.45M | 6M | 7.25M | 7.34M | 8.51M |
| OpEx % of Revenue | 25.12% | 100.43% | 41.43% | 55.03% | 60.1% | 39.1% | 31.14% | 47.83% | 160.14% | 69.09% | 70.94% | 24.25% |
| Selling, General & Admin | 3.05M | 3.53M | 2.93M | 2.62M | 2.6M | 3M | 2.6M | 3.48M | 3.12M | 4.14M | 3.67M | 4.03M |
| SG&A % of Revenue | 9.04% | 38.65% | 16.41% | 16.76% | 25.74% | 16.46% | 14.45% | 25.86% | 83.11% | 39.51% | 35.48% | 11.49% |
| Research & Development | 5.43M | 5.63M | 4.47M | 5.99M | 3.48M | 4.12M | 3M | 2.96M | 2.89M | 3.1M | 3.67M | 4.47M |
| R&D % of Revenue | 16.08% | 61.77% | 25.02% | 38.27% | 34.36% | 22.64% | 16.69% | 21.98% | 77.03% | 29.58% | 35.47% | 12.76% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | 21.15M | -4.66M | 2.13M | 1.17M | -4.14M | 7.21M | 3.99M | -2.43M | -4.86M | -5.62M | -1.89M | 20.42M |
| Operating Margin % | 62.65% | -51.06% | 11.94% | 7.49% | -40.99% | 39.57% | 22.22% | -18.01% | -129.56% | -53.55% | -18.24% | 58.22% |
| Operating Income Growth % | 610.16% | -164.61% | -46.6% | 148.29% | 14.64% | 228.39% | 311.5% | -111.88% | -97.48% | -125.05% | 39.62% | 469.68% |
| EBITDA | 21.55M | -4.27M | 2.5M | 1.53M | -3.8M | 7.54M | 4.32M | -2.11M | -4.53M | -5.3M | -1.58M | 20.71M |
| EBITDA Margin % | 63.85% | -46.82% | 14.02% | 9.78% | -37.57% | 41.4% | 24.05% | -15.64% | -120.97% | -50.56% | -15.29% | 59.06% |
| EBITDA Growth % | 667.25% | -156.62% | -42.06% | 172.68% | 16.21% | 242.27% | 373.07% | -110.18% | -108.08% | -138.83% | 44.53% | 494.1% |
| D&A (Non-Cash Add-back) | 404K | 387K | 372K | 360K | 346K | 334K | 329K | 319K | 322K | 313K | 305K | 293K |
| EBIT | 21.15M | -4.66M | 2.13M | 1.17M | -4.14M | 7.32M | 4.14M | -1.91M | -4.34M | -5.65M | -1.26M | 20.95M |
| Net Interest Income | -5K | -118K | 108K | -511K | 413K | 107K | -148K | 155K | 123K | -811K | 168K | -774K |
| Interest Income | 188K | 265K | 288K | 272K | 419K | 113K | 151K | 522K | 513K | -37K | 628K | 531K |
| Interest Expense | 193K | 383K | 180K | 783K | 6K | 6K | 299K | 367K | 390K | 774K | 460K | 1.3M |
| Other Income/Expense | -5K | -118K | 108K | -511K | 413K | 107K | -148K | 155K | 123K | -811K | 168K | -774K |
| Pretax Income | 21.14M | -4.78M | 2.24M | 661K | -3.73M | 7.32M | 3.84M | -2.27M | -4.73M | -6.43M | -1.72M | 19.65M |
| Pretax Margin % | 62.64% | -52.36% | 12.54% | 4.22% | -36.9% | 40.16% | 21.4% | -16.86% | -126.28% | -61.28% | -16.62% | 56.01% |
| Income Tax | 2.82M | 728K | -116K | 497K | -113K | 822K | 607K | -69K | -138K | -382K | 133K | 308K |
| Effective Tax Rate % | 13.36% | -15.24% | -5.18% | 75.19% | 3.03% | 11.24% | 15.79% | 3.04% | 2.92% | 5.94% | -7.74% | 1.57% |
| Net Income | 18.32M | -5.5M | 2.35M | 164K | -3.62M | 6.49M | 3.24M | -2.2M | -4.59M | -6.04M | -1.85M | 19.34M |
| Net Margin % | 54.27% | -60.34% | 13.19% | 1.05% | -35.79% | 35.65% | 18.02% | -16.35% | -122.6% | -57.64% | -17.9% | 55.14% |
| Net Income Growth % | 606.13% | -184.76% | -27.22% | 107.44% | 21.24% | 207.45% | 274.73% | -111.39% | -46.76% | -61.6% | 48.08% | 462.56% |
| Net Income (Continuing) | 18.32M | -5.5M | 2.35M | 164K | -3.62M | 6.49M | 3.24M | -2.2M | -4.59M | -6.04M | -1.85M | 19.34M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 0.22 | -0.07 | 0.03 | 0.00 | -0.05 | 0.09 | 0.03 | -0.03 | -0.06 | -0.08 | -0.02 | 0.21 |
| EPS Growth % | 566.1% | -180.49% | -10.98% | 106.67% | 21.33% | 203.38% | 252.49% | -114.29% | -20% | -13.74% | 68.43% | 290.91% |
| EPS (Basic) | 0.23 | -0.07 | 0.03 | 0.00 | -0.05 | 0.09 | 0.04 | -0.03 | -0.06 | -0.08 | -0.03 | 0.29 |
| Diluted Shares Outstanding | 83.05M | 78.55M | 80.81M | 81.27M | 76.61M | 81.06M | 81.22M | 73.31M | 73.04M | 72.95M | 83.78M | 83.2M |
| Basic Shares Outstanding | 79.85M | 78.55M | 79.28M | 78.66M | 76.61M | 73.55M | 73.55M | 73.31M | 73.04M | 72.95M | 72.28M | 67.16M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |